Last reviewed · How we verify
Sumatriptan 5%
At a glance
| Generic name | Sumatriptan 5% |
|---|---|
| Also known as | Sumatriptan |
| Sponsor | Express Specialty Pharmacy |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002) (PHASE1)
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030) (PHASE3)
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029) (PHASE3)
- Exploration of Cluster Headache in a PET-MRI Study
- A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain (PHASE2)
- Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation (PHASE1)
- Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan (PHASE1)
- Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sumatriptan 5% CI brief — competitive landscape report
- Sumatriptan 5% updates RSS · CI watch RSS
- Express Specialty Pharmacy portfolio CI